Invention Grant
- Patent Title: Azaindole kinase inhibitors
- Patent Title (中): Azaindole激酶抑制剂
-
Application No.: US10622593Application Date: 2003-07-18
-
Publication No.: US06969717B2Publication Date: 2005-11-29
- Inventor: Rajeev S. Bhide , Rejean Ruel , Carl Thibault , Alexandre L'Heureux
- Applicant: Rajeev S. Bhide , Rejean Ruel , Carl Thibault , Alexandre L'Heureux
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent Elliott Korsen
- Main IPC: A61K31/53
- IPC: A61K31/53 ; A61K31/5377 ; A61K31/541 ; A61K31/662 ; A61K45/00 ; A61K45/06 ; A61P1/04 ; A61P1/16 ; A61P3/04 ; A61P3/10 ; A61P7/06 ; A61P9/00 ; A61P9/06 ; A61P9/08 ; A61P9/10 ; A61P11/00 ; A61P11/06 ; A61P13/08 ; A61P13/10 ; A61P13/12 ; A61P15/00 ; A61P17/00 ; A61P17/02 ; A61P17/06 ; A61P19/00 ; A61P19/02 ; A61P19/10 ; A61P21/04 ; A61P25/00 ; A61P25/02 ; A61P25/16 ; A61P25/28 ; A61P27/02 ; A61P27/16 ; A61P29/00 ; A61P31/10 ; A61P31/12 ; A61P31/18 ; A61P31/22 ; A61P35/00 ; A61P35/02 ; A61P35/04 ; A61P37/00 ; A61P37/02 ; A61P37/04 ; A61P37/06 ; A61P43/00 ; C07D487/02 ; C07D487/04 ; C07F9/6561 ; C07D484/04
Abstract:
The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
Public/Granted literature
- US20040063707A1 Azaindole kinase inhibitors Public/Granted day:2004-04-01
Information query
